HC Wainwright & Co. maintained its Krystal Biotech [KRYS] rating to the equivalent of Buy but changed the price target to $84.0 from $68, in a research note dated 2021-01-08. That figure represents around a 28.74% premium from where the company’s shares closed on Thursday. Some new analysts also started their coverage, with Evercore ISI’s analysts assigning the shares to “an Outperform” rating in a research note to investors issued in early June. Meanwhile, Goldman had launched its coverage on KRYS with “Neutral”, in a research note produced for clients September 24, 2019. In addition, there was no change from H.C. Wainwright on August 06, 2019. The rater maintained KRYS to “a Buy” but assigned new target price of $59.
Is Krystal Biotech Inc. [NASDAQ:KRYS] a Good Buy Right Now?
It should be noted that KRYS technical indicators for short, intermediate as well as long term progress have placed an overall average of 100% as Buy. The average signal changed from 100% Buy in the last week and compares with 88% Buy in the past month. Data from Krystal Biotech Inc.’s Trend Spotter indicated that the signals were Strongest. The stock current average is 0.16 million shares in the past 20 days and the short term average signal indicates a 100% Buy. In the last 50 days, the average trading volume was 0.16 million shares while the medium term average advocated for 100% Buy. The average long-term signal stands at 100% Buy and the 100-day average volume stands at 0.14 million shares.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
KRYS Price Performance
On Wall Street, Krystal Biotech Inc. [NASDAQ:KRYS] finished Thursday’s session up 3.11% at $65.25. The stock went up to $66.50 at the same session while its lowest single day price was $63.69. In the last five days, it saw a rise of about 8.01%, Krystal Biotech Inc. shares gained by almost 8.75% since the beginning of the year. However, the share price has dropped to as low as -2.39% below its one year high. On 01/06/21, the company shares recorded $66.53, the highest single-day price it has got to in the last 52-weeks and a 52-week low was seen on 01/04/21, the same year at $57.06. The company’s shares have inclined by 26.38% in the past year. The 50-day SMA achieved is $51.64 while the 200-day SMA is $47.28. Volume dropped to 0.12 million from 0.31 million in the previous session.
KRYS Stock Support And Resistance Levels
On the 24-hour scale, the immediate backing is perceived around 63.79 level, and in case of violation of this particular level, it will cause more drop to 62.34 level. On the upper level, 67.96 is still the key resistance. The stock may increase to the subsequent resistance at 66.60. The Relative Strength Index (RSI) pinned on the 14-day chart is 70.03, implying a overbought technical stance while the MACD stands at 2.97, meaning price will increase in the next trading period. Percent R indicator moved to 12.79%, implying bullish price movement. Stochastic %K at 80.74% suggest selling the stock.
What is the short interest in Krystal Biotech Inc.?
Short interest in the Krystal Biotech Inc. stock has surged, increasing by 90000.0 shares to total 1.34 million shares on Dec 14, 2020. The interest had seen shares on Nov 12, 2020 stand at 1.43 million, data from Yahoo Finance shows. The decrease of -6.72% suggests the stock saw some decreased bullish sentiment. The stock’s days to cover (short ratio) moved to while the shorted shares account for just 8.98% of the overall float for the stock.
Krystal Biotech Inc.’s Biggest Shareholders: Who Owns Krystal Biotech Inc. [KRYS]?
Filings by Redmile Group LLC showed that the firm now holds a total of 1,501,945 shares or roughly 7.62% of the outstanding KRYS shares. This means their shares have increased by 92,200 from the 1,501,945 the investor reportedly held in its prior 13-F filing. With the conclusion of the purchase, Fidelity Management & Research Co updated stake is worth $73,030,973. Details in the latest 13F filings reveal that BlackRock Fund Advisors acquired their 11.15% stake valued at $45,359,013 while Baker Bros. Advisors LP cut theirs at $42,589,048. During the last quarter, BlackRock Fund Advisors raised 82,819 of its shares in Krystal Biotech Inc. while Baker Bros. Advisors LP sold -42,439 shares. The Credit Suisse Securities’s holdings currently number 774,254 shares at $50520073.5. According to the firm’s last 13F report, The Vanguard Group, Inc. shares in the company at filing stood at 695,321 shares, roughly $38,200,936.